The selective estrogen receptor (ER) modulator (SERM) acolbifene (ACOL), a potent and pure antiestrogen in the mammary gland and uterus, exerts beneficial pro-estrogenic actions on energy balance, insulin sensitivity and lipid metabolism. ACOL binds ERs a and b, both of which have been involved in the metabolic actions of estrogen. This study aimed at determining the identity of the ER involved in the beneficial metabolic actions of ACOL. DESIGN AND MEASUREMENTS: ACOL was administered for 4 weeks to male and female wild-type and ERa knockout (KO) mice, and indices of energy balance as well as plasma and liver lipid concentrations were determined. RESULTS: ERa KO mice were heavier, gained more fat mass and had larger adipose depots than their wild-type counterparts. In both genders, ACOL decreased fat gain (50%) and white adipose tissue mass in male and female wild-type, but not in ERa KO mice. ACOL reduced plasma cholesterol in female wild-type mice (À27%), whereas the compound remained ineffective in their ERa KO counterparts. Plasma triglycerides were unaffected by ACOL. Finally, ACOL decreased liver cholesterol and triglyceride concentrations only in wild-type female animals. CONCLUSION: The beneficial metabolic actions of the SERM ACOL on adiposity and on plasma and liver lipids are entirely due to its interaction with the ERa.
Introduction
Loss of estrogen is largely recognized as the principal cause of the increased risk for atherosclerosis and osteoporosis associated with menopause. 1, 2 Increased weight gain seen at menopause undoubtedly contributes to the increase in cardiovascular risk, as is the case in men throughout life. 3, 4 The plasma lipoprotein profile constitutes another important cardiovascular risk factor, 5 and menopause is associated, among other changes, with a shift in cholesterol lipoprotein distribution toward low-density lipoproteins (LDL), away from high-density lipoproteins. Estrogen is well known to modulate adipose tissue and lipid metabolism in women, but it remains unclear as to which of the a (ERa) or b (ERb) estrogen receptor (ER) is involved, or whether both receptors contribute to such modulation. The study of mice invalidated for the ERa (ERa knockout (KO)), ERb (BERKO) or both (DERKO) genes has increased our understanding of the modulation of body weight and fat deposition by estrogen. Invalidation of the ERa gene increases body weight through increased adipose tissue deposition and increased food efficiency without apparent changes in food intake. 6 Mice with invalidation of the aromatase gene (ArKO), the enzyme that favors the synthesis of estrogen, also confirm the involvement of estrogen in fat deposition. 7 However, the implication of ERb in energy balance and lipid metabolism remains unclear. Some studies suggest that it has effects opposite to those of ERa, 8 whereas,
conversely, others support its involvement in the anorectic action of estrogen. 9 The changes in energy balance and lipid metabolism in women are neutralized to a certain extent by hormone replacement therapy (HRT). 10 However, the recent findings of the Women's Health Initiative study showing that HRT does not protect women against cardiovascular disease, 11 along with the increased risk of breast cancer associated with HRT, 12, 13 emphasize the need for the development of alternative therapies to prevent the undesirable consequences of menopause. Selective estrogen receptor modulators (SERMs), which reduce the risk of estrogen-related cancers but at the same time display estrogen-like actions in other metabolic pathways, constitute a promising avenue for such alternative therapies. 14 We have previously demonstrated beneficial changes in body weight and the lipid profile of female rats following chronic treatment with the fourth-generation SERM Acolbifene (ACOL). 15, 16 The drug was shown in rats to decrease greatly body weight gain, mostly fat mass, mainly through a reduction in food intake. ACOL also increased insulin sensitivity and brought about a major decrease in plasma cholesterol. 15, 16 The SERM binds to both ERa and ERb with much higher affinity than estrogen. 14 Given this and the above-mentioned uncertainties that remain regarding the respective involvement of ERa and ERb in the modulation of energy balance and lipid metabolism, the present study was designed to determine whether the metabolic actions of ACOL were solely due to its interaction with the ERs, and if so, to establish the identity of the receptor. To this end, mice invalidated for the ERa receptor and their wild-type counterparts were treated with ACOL for 4 weeks, and variables of energy and lipid metabolism were assessed. A loss of action of ACOL in ERa KO mice would identify the ERa as the major intermediate of its metabolic actions, whereas their total or partial maintenance would indicate the involvement of either ERb or ER-independent, pleiotropic pathways.
Materials and methods

Animals and treatments
A total of 72 mice from two strains were used. The first strain, with a C57/B6 genetic background, 17 Body weight, body weight gain, body composition, food intake and food efficiency Food intake and body weight were monitored every other day. At the end of the experiment, the animals were allowed access to food until 0800, at which time the last dose of ACOL or vehicle was given. Food was then removed, and mice were killed 6 h later. At the beginning and end of the experiment, body composition (fat and lean mass) and bone mass density (BMD) were determined by dual X-ray absorptiometry (DEXA, PIXImus, GE Lunar Corporation, Madison, WI, USA) under halothane anesthesia. The difference between initial and final composition was computed, and data are presented as mass gain over the 28-day experimental period. Food efficiency was calculated as g body weight gain per 100 g food ingested and is expressed as %.
Blood and tissue collection
At the time of killing, mice were anesthetized with ketamine-xylazine, blood was collected by cardiac puncture into an EDTA-containing syringe, and was then centrifuged at 1500 Â g, 41C for 15 min. Plasma was stored at À201C for later biochemical measurements. Retroperitoneal and inguinal white adipose tissues, taken as being representative of visceral and subcutaneous fat, respectively, interscapular brown adipose tissue (BAT), the soleus and red vastus lateralis muscle (VLM) were excised and weighed. A sample of liver was also excised and immediately frozen in liquid nitrogen.
Acolbifene in ERa KO mouse C Lemieux et al Plasma/tissue measurements Plasma total cholesterol was quantified using a reagent kit from Boehringer Mannheim (Montreal, Quebec, Canada). Plasma triglycerides were assayed by an enzymatic method using a reagent kit from Boehringer Mannheim, which allowed correction for free glycerol. After thawing of the frozen liver samples, total lipids were extracted according to the method of Folch et al 19 and solubilized in isopropanol.
Cholesterol and triglycerides were quantified in the liver lipid extracts using the above-mentioned reagent kits.
Statistical analysis
Data are expressed as means7s.e.m. Some variables were log transformed before analysis to ensure homogeneity of variance. Main and interactive treatment effects were analyzed separately for each gender using 2 Â 2 factorial analysis of variance (ANOVA). The factors were Genotype with two levels (Wild type, ERa KO) and Drug treatment with two levels (Placebo, ACOL). Pairwise mean comparisons were performed to locate individual between-group differences using post hoc Fisher's protected least significant difference (PLSD) test. Differences were considered statistically significant at Po0.05.
Results
The effect of the invalidation of the ERa gene and of ACOL treatment on body weight and cumulative weight gain are depicted in Figure 1 . Body weight did not increase much during the course of treatment, as expected in the 5-monthold mice. In female mice, KO of the ERa gene resulted in an Acolbifene in ERa KO mouse C Lemieux et al increased body weight (Figure 1a ), the mice weighing nearly 7 g (29%) more than their wild-type counterparts of the same age at the inception of drug treatment. Final body weight remained significantly higher in KO than in wildtype mice regardless of drug treatment. ACOL tended to reduce body weight in wild-type mice, but not in the ERa KO animals, and therefore slightly amplified the genotyperelated difference in body weight. In male mice, ERa KO animals weighed over 3 g (11%) more than wild-type mice, but the difference reached significance only in ACOL-treated mice ( Figure 1b ). In the female cohort, genotype and drug treatment interacted significantly on body weight gain over the 28 days of ACOL administration (Figure 1c) . The interaction came from the fact that, whereas ACOL reduced body weight gain in þ / þ mice, the drug tended to exert an opposite action in -/-animals, such that weight gain was significantly greater in ACOL-treated -/-than wild-type mice. As depicted in Figure 1a , ACOL treatment began to reduce weight gain in wild-type mice early on, the effect reaching significance at day 25 until the end of treatment. In the male cohort (Figure 1d ), ACOL prevented body weight gain in wild-type, but not in ERa KO mice. The effects of genotype and ACOL treatment on cumulative food intake, food efficiency and BMD are depicted in Figure 2 . In female mice, genotype and ACOL interacted on cumulative food intake ( Figure 2a) . The interaction came from the fact that, whereas genotype per se did not influence food intake, ACOL tended to slightly reduce food consumption in þ / þ mice but increased the latter in ERa KO mice. Detailed analysis of food intake patterns (data not shown) revealed that ACOL decreased food intake in wild-type female mice only in the first few days of treatment (corresponding to the phase during which body weights became slightly divergent), and that it increased food intake in ERa KO mice mostly during the first half of the treatment period (also corresponding to the greatest difference in body weight). In male mice, no difference in food intake related to the experimental conditions was observed (Figure 2b) . In female mice, genotype and drug treatment interacted significantly on food efficiency (Figure 2c ). Indeed, whereas ACOL reduced food efficiency in þ / þ mice, the drug tended to exert an opposite action in ERa KO animals, such that food efficiency was significantly greater in ACOLtreated ERa KO than wild-type mice. In male mice (Figure 2d ), the pattern of effects of genotype and ACOL on food efficiency was identical to that seen in females. In female mice, ERa gene invalidation prevented the increase in BMD observed over the course of the 28-day experimental period (Figure 2e ), whereas ACOL treatment did not affect the latter. In male mice, no significant effect of genotype and drug treatment on BMD was seen (Figure 2f ).
The treatment effects on body weight gain were closely reflected in those on fat mass gain and adipose depot weights ( Figure 3 ). In fact, body weight gain was largely explained by fat gain, as evidenced by their strong correlation (females: r ¼ 0.78, Po0.0001, n ¼ 34; males: r ¼ 0.87, Po0.0001, n ¼ 37). In female mice, ERa KO animals displayed higher fat mass gain than their wild-type counterparts over the 28-day treatment period (Figure 3a) , as well as larger final inguinal (Figure 3c ) and retroperitoneal (Figure 3d ) adipose depot weights. In wild-type females, ACOL reduced all three indices of adiposity to roughly half of the values seen in untreated mice, whereas the drug remained completely ineffective in altering fat gain and depot weights in ERa KO animals. Male mice displayed more modest changes in response to ERa invalidation and ACOL treatment compared with female mice. Indeed, in untreated male mice, the absence of ERa did not affect fat mass gain over the treatment period (Figure 3b ), but had an overall increasing effect on inguinal (Figure 3d ) and epididymal (Figure 3f ) fat Acolbifene in ERa KO mouse C Lemieux et al pad weights, as determined by ANOVA analysis, relative to their wild-type counterparts. ACOL reduced fat mass gain in wild-type, but not in ERa KO male mice (Figure 3d ), an effect that was reflected in lower mass of the wild-type retroperitoneal (Figure 3f ), but not the inguinal depot (Figure 3e) . Differences between absolute body weight gain and fat mass gain were explained by the slight decrease in total nonfat (lean þ water) mass (not shown) that occurred in all groups over the treatment period.
In female mice, BAT became larger in ERa KO animals compared with wild-type animals (Table 1) , such effect, as determined visually, being apparently due to increased fat deposition. ACOL did not affect BAT mass. In male mice, similar trends were observed, except that the difference in BAT weight between untreated wild-type and ERa KO mice did not reach significance (P ¼ 0.08). The weights of representative skeletal muscles were also determined, and in both female and male mice, they were found not to be notably influenced by either genotype or drug treatment ( Table 1) .
As shown in Figure 4a , in female mice, ERa invalidation resulted in a significant hypercholesterolemia. ACOL treatment decreased plasma cholesterol by 28% in wild-type mice, but remained without effect in ERa KO animals (genotype-drug interaction). In male mice (Figure 4b ), ERa invalidation tended (P ¼ 0.06) to increase cholesterolemia, whereas ACOL displayed a weak tendency to reduce the latter. In female mice, triglyceridemia was also elevated in ERa KO mice compared with wild-type animals (Figure 4c ), and ACOL remained without effect. In male mice (Figure 4d ), neither the genotype nor the drug impacted triglyceridemia.
Liver lipids impact lipoprotein assembly and secretion and were therefore quantified. As shown in Figure 5a , in female mice, ERa invalidation did not affect liver cholesterol concentration. The latter was significantly decreased by ACOL in þ / þ , but not in -/-mice (genotype-drug interaction). In male mice, ERa invalidation did increase Acolbifene in ERa KO mouse C Lemieux et al liver cholesterol concentration, and ACOL remained without effect in either genotype (Figure 5b ). The determination of the activity of major enzymes of hepatic cholesterol synthesis, hydroxymethylglutaryl coenzyme A (HMGCoA) reductase, and of intracellular storage, acylCoA:cholesterol acyltransferase (ACAT), established that genotype and ACOL did not impact liver and plasma cholesterol concentrations through modulation of these enzymes (data not shown). In female mice, liver triglyceride concentration was higher in -/-than in þ / þ animals, but such genotype-related difference was mainly due to the fact that ACOL reduced liver triglycerides in þ / þ , but not in -/-mice (genotypedrug interaction, Figure 5c ). In male mice, the increase in liver triglycerides associated with ERa invalidation was particularly marked (B3-fold). The tendency for ACOL to decrease liver triglycerides did not reach significance.
Discussion
The objective of this study was to determine the identity of the ER involved in the beneficial metabolic actions of the SERM ACOL. To this end, the drug was administered for 4 weeks to wild-type and ERa KO mice, and indices of energy balance as well as plasma and liver lipid concentrations were determined. The present data demonstrate that the marked ACOL-induced reduction in body fat accretion and cholesterolemia are entirely explained by its interaction with the ERa. Both female and male ERa KO mice displayed an increased body weight compared with their wild-type counterparts. The increase in body weight was associated with an increased fat mass, in accordance with the ERa KO phenotype described in previous studies. 6, 20 The mice used here were 5 months old at the beginning of the study and they did not gain much weight (1-2 g) during the 28-day study period. At the onset of the study, the ERa KO mice already weighed more than the wild-type animals and, in accordance with other studies, 6, 7, 20 were therefore well within the weight differentiation phase during which KO mice display higher body weight than the wild-type animals. Such phase is initiated at 3 months of age and is maximal between puberty and adulthood (4-12 months). Treatment of þ / þ mice with ACOL prevented weight gain and its associated fat accumulation. This estrogen-like effect of the SERM confirms previous findings in intact and ovariectomized rats, in which ACOL treatment was shown to reduce markedly weight (mainly fat) accretion. [14] [15] [16] In both Acolbifene in ERa KO mouse C Lemieux et al female and male ERa KO mice, ACOL was unable to prevent weight and fat gain, and even tended to increase weight gain in female mice. This finding establishes that the lowering action of ACOL on weight gain is mediated via an interaction with the ERa.
Although a direct role of the ERb in the regulation of energy balance remains unclear, it is not excluded that the receptor is somehow involved in the modulation of body weight. In studies of ERa, ERb (BERKO) and double (DERKO) KO models by Ohlsson et al, 20 fat mass was found to be decreased in BERKO compared with wild-type mice, which is in clear contrast with the effect of ERa invalidation. Furthermore, in studies of ovariectomized ERa KO, BERKO and DERKO mice, gonadal fat mass was found to be reduced by estrogen administration in wild-type and BERKO, but not in ERa KO and DERKO mice. 21 Using ovariectomized ERa KO mice, Naaz et al 8 concluded that the ERb may exert a lipogenic action in adipose tissue. The findings of the present study in female animals lend some support to such a proposition; in fact, in female ERa KO mice, interaction of ACOL with the ERb tended to slightly increase body weight and fat mass gain, although not significantly so. As in the case of natural estrogen, such a lipogenic effect of ACOL through the ERb would clearly be overwhelmed in wild-type animals by the interaction of the SERM with ERa. In rat models, the ACOL-induced reduction in fat accretion is associated with a frank reduction in food intake, with perhaps some contribution from decreased food efficiency. 15, 16 This anorectic action of ACOL is akin to that of natural estrogen, which has been shown in numerous studies to decrease food intake in rats. 22, 23 In the present study however, despite a transient initial reduction in food consumption, cumulative food intake of female and male wild-type mice was not greatly affected by ACOL treatment. The anorectic action of estrogen is less clearly established in the mouse than in the rat, and the available reports 6, 7, 9, 24, 25 do not allow to conclude definitively regarding the regulation of food intake by estrogen and its receptors in the mouse. In the present study, the effect of ERa invalidation and ACOL treatment on food intake was rather mild, whereas their impact on body weight and fat accretion paralleled changes in food efficiency. The determinants of food efficiency that are involved remain unknown. However, ERa KO mice have been reported to display lower energy expenditure than wild-type mice, 6 and the ArKO mouse model (without endogenous estrogen) displays decreased physical activity with no change in resting energy expenditure. 7 Clearly, further studies specifically aimed at assessing determinants of energy balance are needed to unravel the precise mechanisms of action of ERs and of ACOL on energy balance in the mouse. KO of the ERa increased plasma cholesterol in both male and female mice. This is in accordance with previous studies in ERa KO 20 and ArKO models, 7, 26 which showed that a deficit in estrogen or its a receptor increases cholesterolemia. Treatment with ACOL decreased cholesterolemia in female wild-type mice while tending to do so in male mice. We have previously observed in the rat a very strong (-50%) cholesterol-lowering action of ACOL. [14] [15] [16] The milder hypo- have been studied in various animal models. Importantly, because ACOL remained totally ineffective in either female or male ERa KO mice, the present findings clearly establish that the hypocholesterolemic effect of ACOL is exerted through its interaction with the ERa. The mechanisms by which SERMs in general, and ACOL in particular, modulate cholesterol metabolism remain to be defined. Estrogen is known to modulate several steps in cholesterol metabolism, including the activity of HMGCoA reductase, the rate-limiting enzyme in de novo cholesterol synthesis, 33, 34 the expression of the LDL receptor, 35, 36 as well as that of enzymes involved in liver cholesterol/bile acid excretion. 26 In the present study, HMGCoA reductase and ACAT activities were found not to be altered by invalidation of the ERa or by ACOL, pointing to pathways other than hepatic cholesterol synthesis and storage, such as increased lipoprotein or cholesterol uptake from the circulation and subsequent excretion. The involvement of these pathways in the ACOL-induced reduction in circulating cholesterol levels remains to be established experimentally. Regarding triglyceridemia, its increase by ERa invalidation may be related to the overall increase in adiposity and the stimulation of triglyceride synthesis and decrease in clearance that typically accompany obesity. The lack of effect of ACOL on hypertriglyceridemia associated with ERa invalidation is congruent with previous studies in rats. 15, 16 Invalidation of the ERa gene appeared to have genderspecific effects on liver lipid concentrations. In female mice, the absence of ERa had no consequence on liver lipids, whereas, in male mice, it tended to increase liver cholesterol while markedly increasing liver triglycerides. Remarkably, ACOL reduced both cholesterol and triglyceride concentrations in the liver of wild-type female mice, whereas it remained without effect in male mice despite identical absolute lipid concentrations in both genders. Importantly, as in the case of fat accretion and cholesterolemia, the lipidlowering action of ACOL in the liver of female mice was found to rely entirely upon its interaction with the ERa, as the drug remained ineffective in KO mice. It is intriguing to note that in intact mice, ACOL, through ERa-mediated mechanisms, impacted liver lipids in the one gender in which the latter were not altered by the absence of the receptor. This may be related to gender-specific differences in the degree of sensitivity of liver lipid metabolism to modulation by steroids.
Our earlier studies in rats 15, 16 have repeatedly shown that ACOL favors a mild cholesterol and triglyceride Acolbifene in ERa KO mouse C Lemieux et al accumulation in the liver of this species, in sharp contrast with the present study in mice. This species difference remains unexplained, particularly regarding triglycerides, but some possible explanations regarding cholesterol can be invoked. Firstly, the absence of a gallbladder in the rat, which exists in mice, may affect the enterohepatic circulation of cholesterol and bile acids and thereby impact liver cholesterol accumulation and excretion as well as their modulation by estrogen and SERMs. Secondly, although the estrogen-mediated modulation of hepatic CYP7A1 (or 7-ahydroxylase), the rate-limiting enzyme in the conversion of cholesterol into bile acids, is similar in both rats and mice, 26,37-39 species differences appear to exist in the modulation of the ATP-binding cassette (ABC)G5 and ABCG8 cholesterol transporters. These are members of the large ABC family of transmembrane proteins, 40 and were recently shown to be essential for cholesterol efflux from the liver to the bile canaliculus and from the intestine. 41 The ABC transporters have also been implicated in mediating estrogen actions on cholesterol transport. 42, 43 In mice, although no direct assessment of the effects of estrogen on ABC transporters has yet been reported, one study 26 had
suggested that ABCG5/G8 are not modulated by estrogen in mice. In contrast, in the rat, the well-known estrogeninduced increase in liver cholesterol content has been shown to be associated with decreased biliary cholesterol and liver ABCG5/G8 expression. 44 Therefore, it can reasonably be suggested that species-related differences in the impact of ACOL on liver cholesterol may be related to the species specificity of the modulation of ABCG5/G8 by steroids. Several SERMs are well known to protect against bone loss related to the menopause-related deficit in estrogen, and a wide variety of studies in multiple species and conditions have demonstrated the efficacy of SERMs to reduce bone turnover, and to prevent bone or BMD loss. 31, 32, 45, 46 The effect of estrogen on BMD is ERa-dependent, 21 and the ERa and ERb appear to exert opposing actions: 47 activation of the ERa promotes longitudinal bone growth, whereas that of the ERb represses it. In the present study, substantial changes in BMD over a 28-day period in 5-month-old mice were obviously not expected, but the data nevertheless point to interesting trends. Firstly, although invalidation of the ERa had no long-term effect on BMD in male mice, there was a much lower increase in BMD in KO female mice than in their wild-type counterparts during the experimental period. Secondly, ACOL tended to decrease slightly BMD gain in male and female ERa KO mice, in accordance with its binding to the ERb favoring repression of longitudinal bone growth. Although no positive effect of ACOL on BMD has been observed in wild-type mice in the present short-term study, the SERM is clearly established as one of the most potent SERMs vis-à-vis the prevention of bone loss. 14 In conclusion, the present study demonstrates the beneficial metabolic effects of ACOL on adiposity and on plasma and liver cholesterol concentrations in a mouse model. These effects were more marked in female than in male wildtype mice, possibly because of higher ER density in the former. In contrast, ACOL remained without beneficial effects with regard to energy balance and lipid metabolism in mice invalidated for the ERa gene, thus demonstrating that the SERM impacts the latter entirely through its interaction with ERa. The eventual demonstration that the beneficial metabolic actions of ACOL also occur in humans may broaden the therapeutic choices available for the prevention and treatment of some of the complications associated with menopause.
